Different cultures. Israeli doctors lean towards if they have a experimental treatment option and the patient understands the risks then they are willing to treat if that is what the patient wants. Australian doctors are much more risk adverse even within a clinical trial.
I personally lean towards the Israeli approach as I think patient autonomy is paramount, but I can understand why Australian doctors prefer to be more cautious since most experimental treatments in oncology offer little benefit and often reduce the patients quality of life.
Ann: Zantrene AML trial in Israel advances to Phase 2, page-186
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
-0.140(7.61%) |
Mkt cap ! $289.4M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.89 | $1.70 | $456.4K | 259.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 8662 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |